PALB2/FANCN: recombining cancer and Fanconi anemia - PubMed (original) (raw)

Review

PALB2/FANCN: recombining cancer and Fanconi anemia

Marc Tischkowitz et al. Cancer Res. 2010.

Abstract

Partner and localizer of BRCA2 (PALB2) was originally identified as a BRCA2-interacting protein that is crucial for key BRCA2 genome caretaker functions. It subsequently became clear that PALB2 was another Fanconi anemia (FA) gene (FANCN), and that monoallelic PALB2 mutations are associated with increased risk of breast and pancreatic cancer. Mutations in PALB2 have been identified in breast cancer families worldwide, and recent studies have shown that PALB2 also interacts with BRCA1. Here, we summarize the molecular functions and clinical phenotypes of this key DNA repair pathway component and discuss how its discovery has advanced our knowledge of both FA and adult cancer predisposition.

© 2010 AACR.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: none

Figures

Figure 1. The BRCA complex of HR repair and tumor suppression

(A) The PALB2 gene locus in chromosome 16p12.2. The image is generated using the NCBI Sequence Viewer and slightly modified. (B) Schematic of the PALB2 protein structure showing its domains responsible for binding with BRCA1, BRCA2 and MRG15. (C) A proposed model of BRCA complex assembly at sites of DNA double strand breaks. It is currently unclear which BRCA1 BRCT domain binding partners (BRIP1/FANCJ, CCDC98-RAP80 or CtIP) exist in the core BRCA1/PALB2/BRCA2 complex. Also, BRCA1 may be recruited to damage sites via two distinct mechanisms- one by interacting with the MRE11/RAD50/NBS1 (MRN) complex and the other via its binding to the CCDC98/RAP80 complex, and it remains to be seen which branch is responsible for PALB2/BRCA2/RAD51 recruitment.

Similar articles

• Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer.
  Reid S, Schindler D, Hanenberg H, Barker K, Hanks S, Kalb R, Neveling K, Kelly P, Seal S, Freund M, Wurm M, Batish SD, Lach FP, Yetgin S, Neitzel H, Ariffin H, Tischkowitz M, Mathew CG, Auerbach AD, Rahman N. Reid S, et al. Nat Genet. 2007 Feb;39(2):162-4. doi: 10.1038/ng1947. Epub 2006 Dec 31. Nat Genet. 2007. PMID: 17200671
• PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene.
  Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A, Reid S, Spanova K, Barfoot R, Chagtai T, Jayatilake H, McGuffog L, Hanks S, Evans DG, Eccles D; Breast Cancer Susceptibility Collaboration (UK); Easton DF, Stratton MR. Rahman N, et al. Nat Genet. 2007 Feb;39(2):165-7. doi: 10.1038/ng1959. Epub 2006 Dec 31. Nat Genet. 2007. PMID: 17200668 Free PMC article.
• PALB2 links BRCA1 and BRCA2 in the DNA-damage response.
  Zhang F, Ma J, Wu J, Ye L, Cai H, Xia B, Yu X. Zhang F, et al. Curr Biol. 2009 Mar 24;19(6):524-9. doi: 10.1016/j.cub.2009.02.018. Epub 2009 Mar 5. Curr Biol. 2009. PMID: 19268590 Free PMC article.
• The Role of PALB2 in the DNA Damage Response and Cancer Predisposition.
  Nepomuceno TC, De Gregoriis G, de Oliveira FMB, Suarez-Kurtz G, Monteiro AN, Carvalho MA. Nepomuceno TC, et al. Int J Mol Sci. 2017 Aug 31;18(9):1886. doi: 10.3390/ijms18091886. Int J Mol Sci. 2017. PMID: 28858227 Free PMC article. Review.
• Exploring the roles of PALB2 at the crossroads of DNA repair and cancer.
  Pauty J, Rodrigue A, Couturier A, Buisson R, Masson JY. Pauty J, et al. Biochem J. 2014 Jun 15;460(3):331-42. doi: 10.1042/BJ20140208. Biochem J. 2014. PMID: 24870022 Review.

Cited by

• Prevalence of PALB2 mutations in Australasian multiple-case breast cancer families.
  Teo ZL, Park DJ, Provenzano E, Chatfield CA, Odefrey FA, Nguyen-Dumont T; kConFab; Dowty JG, Hopper JL, Winship I, Goldgar DE, Southey MC. Teo ZL, et al. Breast Cancer Res. 2013 Feb 28;15(1):R17. doi: 10.1186/bcr3392. Breast Cancer Res. 2013. PMID: 23448497 Free PMC article.
• Comparison of Patient Susceptibility Genes Across Breast Cancer: Implications for Prognosis and Therapeutic Outcomes.
  Peleg Hasson S, Menes T, Sonnenblick A. Peleg Hasson S, et al. Pharmgenomics Pers Med. 2020 Jul 27;13:227-238. doi: 10.2147/PGPM.S233485. eCollection 2020. Pharmgenomics Pers Med. 2020. PMID: 32801835 Free PMC article. Review.
• PALB2 self-interaction controls homologous recombination.
  Buisson R, Masson JY. Buisson R, et al. Nucleic Acids Res. 2012 Nov 1;40(20):10312-23. doi: 10.1093/nar/gks807. Epub 2012 Aug 31. Nucleic Acids Res. 2012. PMID: 22941656 Free PMC article.
• Prevalence of PALB2 Germline Mutations in Early-onset and Familial Breast/Ovarian Cancer Patients from Pakistan.
  Rashid MU, Khan FA, Muhammad N, Loya A, Hamann U. Rashid MU, et al. Cancer Res Treat. 2019 Jul;51(3):992-1000. doi: 10.4143/crt.2018.356. Epub 2018 Oct 11. Cancer Res Treat. 2019. PMID: 30309218 Free PMC article.
• Germline genetic landscape of pediatric central nervous system tumors.
  Muskens IS, Zhang C, de Smith AJ, Biegel JA, Walsh KM, Wiemels JL. Muskens IS, et al. Neuro Oncol. 2019 Nov 4;21(11):1376-1388. doi: 10.1093/neuonc/noz108. Neuro Oncol. 2019. PMID: 31247102 Free PMC article. Review.

References

1. 1. Auerbach AD. Fanconi anemia and its diagnosis. Mutat Res. 2009;668:4–10. - PMC - PubMed
2. 1. de Winter JP, Joenje H. The genetic and molecular basis of Fanconi anemia. Mutat Res. 2009;668:11–19. - PubMed
3. 1. Howlett NG, Taniguchi T, Olson S, Cox B, Waisfisz Q, De Die-Smulders C, et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science. 2002;297:606–609. - PubMed
4. 1. Thorslund T, West SC. BRCA2: a universal recombinase regulator. Oncogene. 2007;26:7720–7730. - PubMed
5. 1. Moldovan GL, D'Andrea AD. How the fanconi anemia pathway guards the genome. Annu Rev Genet. 2009;43:223–249. - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • PubMed Central
  • Silverchair Information Systems

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal